362 results
DEFA14A
IMGN
Immunogen, Inc.
29 Jan 24
Additional proxy soliciting materials
5:01pm
may not be able to obtain adequate price and reimbursement for any approved products, including the potential for delays or additional difficulties
8-K
IMGN
Immunogen, Inc.
29 Jan 24
Other Events
5:00pm
with regulatory authorities; the risk that ImmunoGen may not be able to obtain adequate price and reimbursement for any approved products, including
DEFA14A
IMGN
Immunogen, Inc.
24 Jan 24
Additional proxy soliciting materials
4:57pm
of anticipated interactions with regulatory authorities; the risk that ImmunoGen may not be able to obtain adequate price and reimbursement for any approved
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
adequate price and reimbursement for any approved products, including the potential for delays or additional difficulties for ELAHERE in light of the FDA
DEFA14A
IMGN
Immunogen, Inc.
8 Jan 24
Additional proxy soliciting materials
4:12pm
and outcome of anticipated interactions with regulatory authorities; the risk that ImmunoGen may not be able to obtain adequate price and reimbursement
8-K
91zf4y
8 Jan 24
Other Events
4:11pm
DEFM14A
n2ssf vgdvqpxhkce
2 Jan 24
Proxy related to merger
4:26pm
PREM14A
787kkw37cov9izhz24k
21 Dec 23
Preliminary proxy related to merger
4:52pm
DEFA14A
z4ex1jy28pe7lr
21 Dec 23
Additional proxy soliciting materials
3:54pm
DEFA14A
7hzbr t4pjv2c0njfa
30 Nov 23
Additional proxy soliciting materials
4:08pm
DEFA14A
EX-2.1
hg33bm
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
97f3 15boqjd9ellg
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
920bmtw8xkb eax76
2 Nov 23
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
6:35am
8-K
EX-99.1
fer6ae53d5ksd9kwqb3g
18 Sep 23
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
6:35am
8-K
EX-99.1
rn75b
31 Jul 23
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
6:40am
8-K
EX-3.1
pn1zq55nzqq0re5u
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:15pm